On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Featured in Mizuho Securities Research Report

Company: Neurocrine Biosciences, Inc. (NBIX)
Category: Analyst Alerts

Neurocrine Biosciences (NASDAQ: NBIX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Neurocrine has announced a list price of $590 for a 30-count bottle of their new product Ongentys for the adjunctive treatment of Parkinson’s disease. This is in-line with Neurocrine’s previous commentary and should not come as a surprise. The company also continues to expect to launch the product later this year after working through supply issues they have been dealing with for the product. We continue to see Ongentys as a modest commercial opportunity with 2028 sales of ~$250M, but the limited additional infrastructure needed for the product could allow for it to still be an important asset for the company. For more details on Ongentys, please see slides 41-45 from our Neurocrine initiation report.”

To request access to the full report, visit http://nnw.fm/SaZ9d

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinson’s disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit www.Neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie).

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217